Literature DB >> 28082437

Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients.

Anne-Mette Lebech1, Anne Gaardsting1, Annika Loft2, Jesper Graff3, Elena Markova4, Anne Kiil Bertelsen2, Jan Lysgård Madsen3, Kim Francis Andersen2, Eric von Benzon2, Morten Helms1, Lars R Mathiesen1, Kim P David1, Gitte Kronborg1, Andreas Kjaer5.   

Abstract

A fast-track pathway has been established in Denmark to investigate patients with serious nonspecific symptoms and signs of cancer (NSSC), who are not eligible to enter an organ-specific cancer program. The prevalence of cancer in this cohort is approximately 20%. The optimal screening strategy in patients with NSSC remains unknown. The aim of the study was to investigate whether 18F-FDG PET/CT was superior to CT as an initial imaging modality in patients with NSSC. In a randomized prospective trial, the imaging modalities were compared with regard to diagnostic performance.
Methods: Two hundred patients were randomized 1:1 to whole-body 18F-FDG PET/CT or CT of the thorax and abdomen as the imaging modality. A tentative diagnosis was established after first-line imaging. The final referral diagnosis was adjudicated by the physician, when sufficient data were available.
Results: One hundred ninety-seven patients were available for analysis because 3 patients withdrew consent before scanning. Thirty-nine (20%) patients were diagnosed with cancer, 10 (5%) with an infection, 15 (8%) with an autoimmune disease, and 76 (39%) with other diseases. In the remaining 57 patients (28%), no specific disease was found. 18F-FDG PET/CT had a higher specificity (96% vs. 85%; P = 0.028) and a higher accuracy (94% vs. 82%; P = 0.017) than CT. However, there were no statistically significant differences in sensitivity (83% vs. 70%) or negative predictive values (96% vs. 92%). No difference in days to final referral diagnosis according to randomization group could be shown (7.2 vs. 7.6 d). However, for the subgroups in which the imaging modality showed a suggestion of malignancy, there was a significant delay to final diagnosis in the CT group compared with the 18F-FDG PET/CT group (11.6 vs. 5.7 d; P = 0.02).
Conclusion: Compared with CT, we found a higher diagnostic specificity and accuracy of 18F-FDG PET/CT for detecting cancer in patients with NSSC. 18F-FDG PET/CT should therefore be considered as first-line imaging in this group of patients.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  FDG-PET/CT; cancer; molecular imaging; prospective study; randomized study

Mesh:

Substances:

Year:  2017        PMID: 28082437     DOI: 10.2967/jnumed.116.175380

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

Review 1.  Unintentional weight loss: what radiologists need to know and what clinicians want to know.

Authors:  Sanjay Rao; Elias George Kikano; Daniel Arnold Smith; Ezgi Guler; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  Abdom Radiol (NY)       Date:  2021-01-01

2.  Extending the Scope of 19F Hyperpolarization through Signal Amplification by Reversible Exchange in MRI and NMR Spectroscopy.

Authors:  Alexandra M Olaru; Thomas B R Robertson; Jennifer S Lewis; Alex Antony; Wissam Iali; Ryan E Mewis; Simon B Duckett
Journal:  ChemistryOpen       Date:  2017-12-21       Impact factor: 2.911

3.  Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.

Authors:  Line Jee Hartmann Rasmussen; Martin Schultz; Anne Gaardsting; Steen Ladelund; Peter Garred; Kasper Iversen; Jesper Eugen-Olsen; Morten Helms; Kim Peter David; Andreas Kjaer; Anne-Mette Lebech; Gitte Kronborg
Journal:  Int J Cancer       Date:  2017-04-24       Impact factor: 7.396

4.  Economic impact of spectral body imaging in diagnosis of patients suspected for occult cancer.

Authors:  Michael Brun Andersen; Dyveke Ebbesen; Jesper Thygesen; Matthijs Kruis; Qing Gu; Ekta Dharaiya; Finn Rasmussen
Journal:  Insights Imaging       Date:  2021-12-20

Review 5.  Application of Green Gold Nanoparticles in Cancer Therapy and Diagnosis.

Authors:  Saman Sargazi; Ushna Laraib; Simge Er; Abbas Rahdar; Mohadeseh Hassanisaadi; Muhammad Nadeem Zafar; Ana M Díez-Pascual; Muhammad Bilal
Journal:  Nanomaterials (Basel)       Date:  2022-03-27       Impact factor: 5.076

6.  Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption.

Authors:  Chuen-Yen Lau; Matthew A Adan; Jessica Earhart; Cassie Seamon; Thuy Nguyen; Ariana Savramis; Lindsey Adams; Mary-Elizabeth Zipparo; Erin Madeen; Kristi Huik; Zehava Grossman; Benjamin Chimukangara; Wahyu Nawang Wulan; Corina Millo; Avindra Nath; Bryan R Smith; Ana M Ortega-Villa; Michael Proschan; Bradford J Wood; Dima A Hammoud; Frank Maldarelli
Journal:  Front Med (Lausanne)       Date:  2022-08-22

7.  18F-fluorodeoxyglucose positron emission tomography/ computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis.

Authors:  Richard Bresler; Harry William Schroeder; David Z Chow; Ruth Lim
Journal:  World J Nucl Med       Date:  2020-01-17

8.  Diagnostic property of direct referral from general practitioners to contrast-enhanced thoracoabdominal CT in patients with serious but non-specific symptoms or signs of cancer: a retrospective cohort study on cancer prevalence after 12 months.

Authors:  Marie Møller; Bue Juvik; Stine Chabert Olesen; Hanne Sandstrøm; Erling Laxafoss; Simon Bertram Reuter; Uffe Bodtger
Journal:  BMJ Open       Date:  2019-12-31       Impact factor: 2.692

9.  Use and diagnostic outcomes of cancer patient pathways in Denmark - is the place of initial diagnostic work-up an important factor?

Authors:  Susanne Oksbjerg Dalton; John Brodersen; Christina Sadolin Damhus; Volkert Siersma; Anna Rubach Birkmose
Journal:  BMC Health Serv Res       Date:  2022-01-31       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.